News Nabriva Therapeutics plc

Equities

NBRVF

IE000OZRGNV6

Delayed OTC Markets Other stock markets 01:24:39 2024-04-17 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	0.00%

2023	Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
2023	Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-10-19	CI
Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index	23-07-31	CI
Sumitomo Pharma Co., Ltd. acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.	23-07-30	CI
Nabriva Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	23-07-24	PU
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer	23-07-10	MT
Nabriva Therapeutics plc Appoints H. Michael Hogan as Chief Executive Officer	23-07-07	CI
Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer	23-07-07	CI
Nabriva Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
NABRIVA THERAPEUTICS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-04-17	AQ
Nabriva Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Nabriva Therapeutics plc Auditor Raises 'Going Concern' Doubt	23-04-16	CI
Nabriva Therapeutics : Material Agreement - Form 8-K	23-02-06	PU
NABRIVA THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	23-02-06	AQ
NABRIVA THERAPEUTICS PLC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	23-01-20	AQ
Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer	23-01-20	CI
Nabriva Therapeutics : Termination of Material Agreement - Form 8-K	23-01-09	PU
NABRIVA THERAPEUTICS PLC : Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits (form 8-K)	23-01-09	AQ
Nabriva Therapeutics Provides Corporate Update	23-01-09	AQ
Health Care Up as Biogen Rises on Alzheimer's Drug Progress -- Health Care Roundup	23-01-06	DJ
Sector Update: Healthcare Stocks Rise Friday, Mostly Trail Other Sectors	23-01-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nabriva Therapeutics plc

Equities

NBRVF

IE000OZRGNV6

Summary

Filters